论文部分内容阅读
LIGHT(TNFSF14)的两个主要受体:HVEM和LTβR,均为TNFR超家族成员。LIGHT-HVEM途径是重要的T细胞共刺激信号途径,而LIGHT-LTβR在改变树突细胞和间质细胞的功能方面发挥重要作用。HVEM还可与两个免疫球蛋白超基因家族成员即抑制T细胞活化的BTLA和CD160相互作用,HVEM在刺激和抑制信号之间充当一种分子开关。人和实验动物模型研究显示LIGHT-LTβR/HVEM途径在自身免疫疾病的炎症反应和病理发生中起重要的免疫调节作用。因此,在免疫相关疾病的免疫干预治疗中,LIGHT是一种良好的潜在靶标。本文就LIGHT-LTβR/HVEM途径在免疫相关疾病中作用的最新研究进展做一综述。
The two major receptors for LIGHT (TNFSF14), HVEM and LTβR, are members of the TNFR superfamily. The LIGHT-HVEM pathway is an important T cell costimulatory pathway, and LIGHT-LTβR plays an important role in altering the function of dendritic cells and interstitial cells. HVEM also interacts with BTLA and CD160, members of two immunoglobulin supergene family members that inhibit T-cell activation, and HVEM acts as a molecular switch between stimulatory and inhibitory signals. Studies in human and experimental animal models have shown that the LIGHT-LT [beta] R / HVEM pathway plays an important immunomodulatory role in the inflammatory response and pathology of autoimmune diseases. Therefore, LIGHT is a good potential target for immune intervention in immune-related diseases. This review summarizes recent advances in the role of the LIGHT-LTβR / HVEM pathway in immune-related diseases.